Perceptive Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,370,851
| Closed | -$90.7M | – | 109 |
|
|
2025
Q4 | $90.7M | Hold |
6,370,851
| – | – | 1.62% | 20 |
|
|
2025
Q3 | $50.2M | Sell |
6,370,851
-1,041,979
| -14% | -$7.42M | 1.45% | 25 |
|
|
2025
Q2 | $42.5M | Sell |
7,412,830
-14,051,697
| -65% | -$90.7M | 1.57% | 17 |
|
|
2025
Q1 | $175M | Sell |
21,464,527
-2,781,425
| -11% | -$25.7M | 6.19% | 3 |
|
|
2024
Q4 | $228M | Sell |
24,245,952
-3,811,504
| -14% | -$39.6M | 6.29% | 3 |
|
|
2024
Q3 | $300M | Hold |
28,057,456
| – | – | 6.34% | 3 |
|
|
2024
Q2 | $278M | Hold |
28,057,456
| – | – | 6.7% | 2 |
|
|
2024
Q1 | $331M | Hold |
28,057,456
| – | – | 5.78% | 2 |
|
|
2023
Q4 | $398M | Buy |
28,057,456
+364,539
| +1% | +$4.14M | 8.89% | 2 |
|
|
2023
Q3 | $337M | Buy |
27,692,917
+30,000
| +0.1% | +$387K | 11.23% | 1 |
|
|
2023
Q2 | $347M | Hold |
27,662,917
| – | – | 10.06% | 1 |
|
|
2023
Q1 | $307M | Buy |
27,662,917
+20,000
| +0.1% | +$247K | 9.06% | 1 |
|
|
2022
Q4 | $338M | Buy |
27,642,917
+270,000
| +1% | +$3.04M | 9.48% | 1 |
|
|
2022
Q3 | $286M | Buy |
27,372,917
+477,385
| +2% | +$5.32M | 8.29% | 1 |
|
|
2022
Q2 | $289M | Sell |
26,895,532
-660,313
| -2% | -$5.44M | 9.05% | 2 |
|
|
2022
Q1 | $261M | Buy |
27,555,845
+996,402
| +4% | +$9.34M | 5.23% | 2 |
|
|
2021
Q4 | $307M | Hold |
26,559,443
| – | – | 4.73% | 4 |
|
|
2021
Q3 | $254M | Buy |
26,559,443
+3,438,114
| +15% | +$35.2M | 3.68% | 6 |
|
|
2021
Q2 | $223M | Buy |
23,121,329
+260,000
| +1% | +$2.54M | 2.89% | 6 |
|
|
2021
Q1 | $226M | Sell |
22,861,329
-2,250,719
| -9% | -$34.8M | 2.86% | 6 |
|
|
2020
Q4 | $580M | Sell |
25,112,048
-10,000
| -0% | -$205K | 6.22% | 2 |
|
|
2020
Q3 | $355M | Sell |
25,122,048
-60,316
| -0.2% | -$879K | 5.18% | 3 |
|
|
2020
Q2 | $380M | Hold |
25,182,364
| – | – | 6.15% | 1 |
|
|
2020
Q1 | $233M | Buy |
25,182,364
+50,000
| +0.2% | +$475K | 6.06% | 5 |
|
|
2019
Q4 | $245M | Buy |
25,132,364
+522,664
| +2% | +$4.78M | 4.86% | 6 |
|
|
2019
Q3 | $197M | Buy |
24,609,700
+3,100,214
| +14% | +$33.6M | 5.32% | 5 |
|
|
2019
Q2 | $268M | Sell |
21,509,486
-130,000
| -0.6% | -$1.65M | 6.16% | 5 |
|
|
2019
Q1 | $294M | Buy |
21,639,486
+915,062
| +4% | +$11.2M | 8.3% | 2 |
|
|
2018
Q4 | $192M | Buy |
20,724,424
+30,000
| +0.1% | +$330K | 7.3% | 3 |
|
|
2018
Q3 | $250M | Buy |
20,694,424
+670,000
| +3% | +$9.37M | 6.69% | 2 |
|
|
2018
Q2 | $313M | Hold |
20,024,424
| – | – | 8.2% | 2 |
|
|
2018
Q1 | $301M | Buy |
20,024,424
+2,135,827
| +12% | +$32.5M | 8.44% | 2 |
|
|
2017
Q4 | $257M | Hold |
17,888,597
| – | – | 8.53% | 2 |
|
|
2017
Q3 | $270M | Buy |
17,888,597
+591,925
| +3% | +$7.83M | 10.31% | 2 |
|
|
2017
Q2 | $174M | Hold |
17,296,672
| – | – | 8.76% | 1 |
|
|
2017
Q1 | $123M | Hold |
17,296,672
| – | – | 7.03% | 3 |
|
|
2016
Q4 | $86M | Buy |
17,296,672
+3,180,028
| +23% | +$22M | 6.11% | 3 |
|
|
2016
Q3 | $104M | Sell |
14,116,644
-1,122,800
| -7% | -$7.58M | 6.74% | 3 |
|
|
2016
Q2 | $83.2M | Hold |
15,239,444
| – | – | 5.77% | 4 |
|
|
2016
Q1 | $129M | Hold |
15,239,444
| – | – | 11.29% | 1 |
|
|
2015
Q4 | $148M | Buy |
15,239,444
+800,000
| +6% | +$7.21M | 10.94% | 1 |
|
|
2015
Q3 | $176M | Hold |
14,439,444
| – | – | 14.03% | 1 |
|
|
2015
Q2 | $204M | Hold |
14,439,444
| – | – | 12.3% | 1 |
|
|
2015
Q1 | $157M | Hold |
14,439,444
| – | – | 12.21% | 1 |
|
|
2014
Q4 | $120M | Buy |
14,439,444
+2,100,000
| +17% | +$14.4M | 10.07% | 1 |
|
|
2014
Q3 | $73.4M | Hold |
12,339,444
| – | – | 7.43% | 1 |
|
|
2014
Q2 | $41.2M | Buy |
12,339,444
+11,373,144
| +1,177% | +$26.7M | 4.04% | 7 |
|
|
2014
Q1 | $2M | Buy |
+966,300
| New | +$2.42M | 0.21% | 67 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Perceptive Advisors's FOLD Position: Q1 2026 in Review
Perceptive Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 6,370,851 shares — an estimated $90.7M sold.
Perceptive Advisors first reported a position in FOLD in Q1 2014 and held it in 48 quarters. The position peaked at $580M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Perceptive Advisors reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
- Perceptive Advisors sold 6,370,851 Amicus Therapeutics shares in Q1 2026, an estimated $90.7M.
- Perceptive Advisors first reported a position in Amicus Therapeutics in Q1 2014 and held it in 48 quarters.
- Perceptive Advisors's Amicus Therapeutics position peaked at $580M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.